Experience
Biogen International GmbH
Teva Pharmaceuticals USA, Inc.
Represented Biogen in a Hatch-Waxman litigation involving twenty-eight companies seeking FDA approval to market generic versions of Tecfidera®.
Biogen International GmbH v. Teva Pharmaceuticals USA, Inc., 1:17-cv-00829, D. Del., Judge Noreika
Biogen International GmbH v. Teva Pharmaceuticals USA, Inc., 1:17-cv-00116, N.D.W. Va., Judge Keeley
Biogen Int’l GmbH v. Amneal Pharmaceuticals LLC et al.
Biogen Int’l GmbH
Pronova Biopharma Norge AS v. Teva Pharmaceuticals USA, Inc.
Pronova Biopharma Norge AS
Abbott Laboratories v. Teva Pharmaceuticals USA, Inc.
Abbott Laboratories
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc.
Eli Lilly and Company
Grünenthal GmbH v. Teva Pharmaceuticals
Grünenthal GmbH
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.